bristol-myers squibb - Search News

News

Bristol Myers Squibb Cuts Full-Year Adjusted View

Seeking Alpha · 1d

Bristol-Myers Squibb: Declines Have Gone Too Far

Bristol-Myers Squibb sees stabilizing sales, growth in key drugs, and raised guidance. Click to read more about why BMY is an undervalued stock and why I rate it a Buy.

Yahoo Finance · 2d

Why Bristol-Myers Squibb (BMY) Stock Is Trading Lower Today

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 4.2% in the afternoon session after the company lowered its full-year earnings forecast, overshadowing second-quarter results that beat revenue expectations.

The Wall Street Journal on MSN · 2d

Bristol Myers Squibb Cuts Full-Year Adjusted View, but Raises Revenue Expectations

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a charge related to its BioNTech partnership.

2d

Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

1don MSN

Bristol-Myers Squibb shares snapped six-session losing streak

Myers Squibb (NYSE:BMY) shares inched up on Friday after six consecutive sessions of fall. The stock was up 2.2% at $44.24.

StockStory.org on MSN2d

Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q2, Full-Year Sales Guidance is Optimistic

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced in Q2 CY2025, but sales were flat year on year at $12.27 ...

2d

Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors

Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...

Fierce Pharma2d

Bristol Myers touts commercial execution, reckons with recent clinical setbacks

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

BioPharma Dive5d

Bain leads $300M investment in startup built on Bristol Myers immune drugs

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

3d

Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors

This was the stock's fifth consecutive day of losses.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results